Mar 6 |
Oncternal Therapeutics Q4 2023 Earnings Preview
|
Feb 29 |
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results
|
Feb 6 |
Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
|
Jan 8 |
Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
|
Jan 4 |
Oncternal Therapeutics announces a reverse stock split
|
Jan 4 |
Oncternal Therapeutics Announces Reverse Stock Split
|
Jan 2 |
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
|
Dec 27 |
Why Reneo Pharmaceuticals Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
|
Dec 26 |
Oncternal slips after early data for lymphoma therapy
|
Dec 26 |
Oncternal Therapeutics Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-cell Lymphoma
|